Ivana Sullivan
Overview
Explore the profile of Ivana Sullivan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
388
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Serra-Lopez J, Pujol-Besora C, Martinez-Recio S, Barba Joaquin A, Riudavets Melia M, Sullivan I, et al.
Eur J Oncol Nurs
. 2025 Feb;
74:102809.
PMID: 39892201
Purpose: To evaluate the impact of an advanced practice nurse (APN) intervention on the reduction of emergency department visits due to immune-related adverse events (irAEs) in patients receiving immunotherapy-based treatments....
2.
Piedra A, Martinez-Recio S, Hernandez A, Moran T, Arriola E, Recuero-Borau J, et al.
Front Oncol
. 2025 Jan;
14:1510278.
PMID: 39741981
Introduction: Pembrolizumab stands as a first-line option for patients with advanced non-small cell lung cancer (NSCLC) and high programmed death-ligand 1 (PD-L1) expression (PD-L1 ≥50%). Several factors such as antibiotic...
3.
Barba A, Lopez-Vilaro L, Ferre M, Majem M, Martinez-Recio S, Bell O, et al.
Pharmaceutics
. 2024 Sep;
16(9).
PMID: 39339159
Standard first-line chemotherapy in small cell lung cancer (SCLC) is based on the platinum plus etoposide combination. Despite a high objective response rate, responses are not durable and chemotherapy-induced toxicity...
4.
Anguera G, Mulet M, Zamora C, Osuna-Gomez R, Barba A, Sullivan I, et al.
Biomedicines
. 2024 May;
12(5).
PMID: 38790920
PD-(L)1 inhibitors are part of the treatment strategy for non-small cell lung cancer (NSCLC) although its efficacy is limited to certain patients. Our study aimed to identify patients who might...
5.
Alserawan L, Mulet M, Anguera G, Riudavets M, Zamora C, Osuna-Gomez R, et al.
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730712
Immune checkpoint inhibitors (ICI) have the potential to trigger unpredictable immune-related adverse events (irAEs), which can be severe. The underlying mechanisms of these events are not fully understood. As PD-L1...
6.
Tagliamento M, Morfouace M, Loizides C, Oliveira J, Greillier L, Raimbourg J, et al.
NPJ Precis Oncol
. 2024 Feb;
8(1):37.
PMID: 38366021
Arcagen (NCT02834884) is a European prospective study aiming at defining the molecular landscape of rare cancers for treatment guidance. We present data from the cohort of rare thoracic tumors. Patients...
7.
Carmona-Rocha E, Aguado M, Tubau C, Sanchez S, Mozos A, Sullivan I, et al.
J Dtsch Dermatol Ges
. 2023 Nov;
21(11):1407-1409.
PMID: 37946658
No abstract available.
8.
Carmona-Rocha E, Sullivan I, Yelamos O
Melanoma Res
. 2023 Oct;
33(6):553-555.
PMID: 37890183
No abstract available.
9.
Carmona-Rocha E, Aguado M, Tubau C, Sanchez S, Mozos A, Sullivan I, et al.
J Dtsch Dermatol Ges
. 2023 Sep;
21(11):1407-1409.
PMID: 37658659
No abstract available.
10.
Nadal E, Rodriguez-Abreu D, Simo M, Massuti B, Juan O, Huidobro G, et al.
J Clin Oncol
. 2023 Aug;
41(28):4478-4485.
PMID: 37603816
Purpose: The Atezo-Brain study evaluated atezolizumab combined with chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) with untreated brain metastases, a population traditionally excluded from trials. Methods: This single-arm...